ArticleBreast cancer (Dove Medical Press)2026
AIM2 Lactylation Regulates Radiotherapy Sensitivity in Triple-Negative Breast Cancer.
Article in Breast cancer (Dove Medical Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited targeted treatment options. Radiotherapy remains an important therapeutic approach for TNBC, but radioresistance markedly limits its efficacy. Absent in melanoma 2 (AIM2) has been increasingly implicated in tumor biology and innate immune signaling; however, its role in TNBC radioresistance and its regulation by the lactate-rich tumor microenvironment remain unclear. Methods: Radiation-resistant TNBC cell models were established from BT-549 and MDA-MB-231 cells by repeated fractional irradiation. AIM2 knockdown and IRF3 overexpression were achieved by lentiviral transduction. Cell proliferation, colony formation, apoptosis, protein expression, AIM2 lactylation, subcellular localization, and AIM2-IRF3 interaction were evaluated using CCK-8 assay, colony formation assay, flow cytometry, RT-qPCR, Western blotting, co-immunoprecipitation, and immunofluorescence. Bioinformatics analyses were performed to assess the potential prognostic relevance of AIM2. In vitro experiments were performed with at least three independent biological replicates. Results: Radiation treatment increased AIM2 expression in TNBC cells. AIM2 knockdown reduced colony formation and promoted apoptosis in radioresistant TNBC cells. High-lactate conditions decreased AIM2 expression, increased AIM2 lactylation, and promoted AIM2 nuclear translocation. IRF3 overexpression partially reversed the effects of AIM2 knockdown on colony formation and apoptosis, whereas lactate treatment weakened the interaction between AIM2 and IRF3. Bioinformatics analyses indicated that elevated AIM2 expression was associated with poorer prognosis. Conclusion: These findings suggest that AIM2 may be involved in the regulation of TNBC radioresistance, potentially through its interaction with IRF3. High-lactate conditions may affect this regulatory axis by enhancing AIM2 lactylation. This study provides preliminary evidence for a potential mechanism linking lactate-mediated post-translational modification with radiosensitivity regulation in TNBC; however, further mechanistic, in vivo, and clinical validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.